| Item Type | Name |
|
Concept
|
Anti-Inflammatory Agents, Non-Steroidal
|
|
Concept
|
Anti-Inflammatory Agents
|
|
Academic Article
|
Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update.
|
|
Academic Article
|
Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis.
|
|
Academic Article
|
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.
|
|
Academic Article
|
Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data.
|
|
Academic Article
|
Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial.
|
|
Academic Article
|
Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease.
|
|
Academic Article
|
A practical, evidence-based guide to the use of adalimumab in Crohn's disease.
|
|
Academic Article
|
Clinical scenarios in IBD: optimizing the use of conventional and biologic agents.
|
|
Academic Article
|
We once were blind and now we see: is it time to treat ulcerative colitis to achieve mucosal healing?
|
|
Academic Article
|
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
|
|
Academic Article
|
5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
|
|
Academic Article
|
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
|
|
Academic Article
|
Will a 5-ASA a day keep the cancer (and dysplasia) away?
|
|
Academic Article
|
Serum adalimumab concentration and clinical remission in patients with Crohn's disease.
|
|
Academic Article
|
What you see is not always what you get: raising the bar on clinical trial methodology in ulcerative colitis.
|
|
Academic Article
|
The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease.
|
|
Academic Article
|
Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease.
|
|
Academic Article
|
Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis.
|
|
Academic Article
|
Vedolizumab in the treatment of Crohn's disease.
|
|
Academic Article
|
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
|
|
Academic Article
|
Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.
|
|
Academic Article
|
Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin.
|
|
Academic Article
|
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
|
|
Academic Article
|
Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases.
|
|
Academic Article
|
Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.
|
|
Academic Article
|
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.
|
|
Academic Article
|
Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares.
|
|
Academic Article
|
Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease.
|
|
Academic Article
|
ACG Clinical Guideline: Ulcerative Colitis in Adults.
|
|
Academic Article
|
Exposure to Anti-tumor Necrosis Factor Medications Increases the Incidence of Pouchitis After Restorative Proctocolectomy in Patients With Ulcerative Colitis.
|
|
Academic Article
|
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease.
|
|
Academic Article
|
Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes.
|
|
Academic Article
|
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary.
|
|
Academic Article
|
Stopping Clinical Trials in Inflammatory Bowel Disease During the COVID-19 Pandemic Is Not a Responsible Act.
|
|
Academic Article
|
Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
|
|
Academic Article
|
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.
|
|
Academic Article
|
Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management.
|
|
Academic Article
|
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.
|
|
Academic Article
|
Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium.
|